NCT06741072View on ClinicalTrials.gov

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

PHASE1RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Chronic Kidney Disease, Stage 4Chronic Kidney Disease, Stage 5EBV-Related Lymphoproliferative DisorderEBV-Related Malignant NeoplasmPost-Transplant Lymphoproliferative Disorder
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Dulbecco''s Phosphate-Buffered Saline

Given SC

BIOLOGICAL

Peptide Vaccine

Given OSU-2131 SC

BIOLOGICAL

QS21

Given SC

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER